Abstract
BackgroundCell culture conditions during manufacturing can impact the clinical efficacy of chimeric antigen receptor (CAR) T cell products. Production methods have not been standardized because the optimal approach remains unknown. Separate CD4+and CD8+cultures offer a potential advantage but complicate manufacturing and may affect cell expansion and function. In a phase 1/2 clinical trial, we observed poor expansion of separate CD8+cell cultures and hypothesized that coculture of CD4+cells and CD8+cells at a defined ratio at culture initiation would enhance CD8+cell expansion and simplify manufacturing.MethodsWe generated CAR T cells either as separate CD4+and CD8+cells, or as combined cultures mixed in defined CD4:CD8 ratios at culture initiation. We assessed CAR T cell expansion, phenotype, function, gene expression, and in vivo activity of CAR T cells and compared these between separately expanded or mixed CAR T cell cultures.ResultsWe found that the coculture of CD8+CAR T cells with CD4+cells markedly improves CD8+cell expansion, and further discovered that CD8+cells cultured in isolation exhibit a hypofunctional phenotype and transcriptional signature compared with those in mixed cultures with CD4+cells. Cocultured CAR T cells also confer superior antitumor activity in vivo compared with separately expanded cells. The positive impact of CD4+cells on CD8+cells was mediated through both cytokines and direct cell contact, including CD40L-CD40 and CD70-CD27 interactions.ConclusionsOur data indicate that CD4+cell help during cell culture maintains robust CD8+CAR T cell function, with implications for clinical cell manufacturing.
Funder
NIH
Mustang Bio
Fred Hutchinson Cancer Center
Kleberg Foundation
Subject
Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献